Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-13Price:$965.35
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-16Price:$964.45
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-20Price:$963.60
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9Price:$962.42
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14Price:$961.59
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-15Price:$960.53
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9Price:$959.47
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2Price:$958.86
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2Price:$957.78
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:McCourt MarionOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-250Price:$964.73
Filings by filing date
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-13Price:$965.35
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-16Price:$964.45
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-20Price:$963.60
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9Price:$962.42
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14Price:$961.59
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-15Price:$960.53
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9Price:$959.47
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2Price:$958.86
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2Price:$957.78
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:McCourt MarionOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-250Price:$964.73
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 777 Old Saw Mill River Road TARRYTOWN NY 10591 |
Tel: | N/A |
Website: | https://www.regeneron.com |
IR: | See website |
Key People | ||
Leonard S. Schleifer Co-Chairman of the Board, President, Chief Executive Officer, Founder | George D. Yancopoulos Co-Chairman of the Board, President, Chief Scientific Officer | Christopher R. Fenimore Chief Financial Officer, Senior Vice President - Finance |
Joseph J. LaRosa Executive Vice President, General Counsel, Secretary | Daniel P. Van Plew Executive Vice President, General Manager - Industrial Operations and Product Supply | Marion E. McCourt Executive Vice President - Commercial |
Andrew J. Murphy Executive Vice President - Research | Neil Stahl Executive Vice President - Research and Development | Jason Pitofsky Vice President, Controller |
Business Overview |
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others. The Company's solid tumor and other oncology and autoimmune cell therapy programs include the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets. |
Financial Overview |
For the fiscal year ended 31 December 2023, Regeneron Pharmaceuticals Inc revenues increased 8% to $13.12B. Net income decreased 9% to $3.95B. Revenues reflect Sanofi segment increase of 33% to $3.8B, Libtay-ROW segment increase from $73M to $324.3M. Net income was offset by Selling, general increase of 25% to $2.32B (expense), Research and development increase of 21% to $2.41B (expense). |
Employees: | 13,450 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $91,362M as of Dec 31, 2023 |
Annual revenue (TTM): | $13,117M as of Dec 31, 2023 |
EBITDA (TTM): | $4,654M as of Dec 31, 2023 |
Net annual income (TTM): | $3,954M as of Dec 31, 2023 |
Free cash flow (TTM): | $3,668M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 109,761,896 as of Jan 25, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |